Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar
Key Points
The FDA will fast-track certain psychedelic treatments.
Several biotech stocks are soaring due to the new policy.
- 10 stocks we like better than Compass Pathways Plc ›
Over the weekend, President Donald Trump fast-tracked the approval process for psychedelic treatments for mental illnesses.
Trump signed an order that directs the Food and Drug Administration (FDA) to ease restrictions on and speed up reviews of certain psychedelic drugs, cutting their review times to one or two months from the previous six to 10 months.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
The order will be a huge boost for makers of psychedelic-based therapies, as they have struggled to attract capital in the past because many investors considered the regulatory environment for such drugs to be too risky.
Three under-the-radar biotech firms in particular are expected to benefit from the new policy.
Compass Pathways (NASDAQ: CMPS), based in London, is evaluating one drug for treatment-resistant depression (TRD) in two Phase 3 studies. The company is also testing the drug for post-traumatic stress disorder and anorexia nervosa.
AtaiBeckley (NASDAQ: ATAI) has three programs currently in clinical testing, two for TRD and one for social anxiety disorder. The New York City-based company is also a major stakeholder in Compass Pathways.
Definium Therapeutics (NASDAQ: DFTX), also headquartered in New York City, is evaluating a psychedelic drug in two studies to treat anxiety disorder and another to treat major depressive disorder.
Trump's weekend order on psychedelic treatments directs the FDA to issue expedited reviews of products with so-called "breakthrough therapy" designated status, which means the FDA believes there is evidence those products could offer substantial improvement over existing options for serious or life-threatening conditions. All three of the companies mentioned above have therapies with that FDA status.
Image source: Getty Images.
And all three stocks rose on Monday. Definium was up more than 4%, AtaiBeckley soared 32%, and Compass Pathways had climbed about 39% in midmorning trading.
The federal government will also add funding for research on psychedelic therapies
The new order also directs the Secretary of Health and Human Services to allocate $50 million to advance private sector research into psychedelic treatments.
The policy change on psychedelic therapies is a return to the past. There was significant progress in the 1950s on using psychedelics to treat addiction and other conditions, but research was curtailed significantly in the 1960s when recreational use of LSD and similar drugs became popular.
Psilocybin, a psychedelic compound found in certain mushrooms, and ibogaine, a psychoactive compound from the root bark of an African shrub, are currently classified as Schedule I drugs, which means they're considered to have no accepted medical use and high potential for abuse.
Trump said his order will expedite the reclassification of those drugs.
A new era has begun for psychedelic treatments for mental disorders. Companies that can bring those treatments to market first are poised to benefit the most.
Should you buy stock in Compass Pathways Plc right now?
Before you buy stock in Compass Pathways Plc, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Compass Pathways Plc wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $524,786!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,236,406!*
Now, it’s worth noting Stock Advisor’s total average return is 994% — a market-crushing outperformance compared to 199% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of April 20, 2026.
Matthew Benjamin has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
